Table 1 Active/ recruiting clinical trials in ovarian cancer patients with different types of therapies
From: Nanotechnology for boosting ovarian cancer immunotherapy
Clinical trial registration number | Study design | Intervention/ Treatment | Type of therapy | Type of ovarian cancer/Patients |
|---|---|---|---|---|
NCT03602586 (Phase II) | Single group assignment and open label | Combination of epacadostat and pembrolizumab | Monoclonal antibody and IDO1 inhibitor | Clear cell carcinoma |
NCT03249142; GINECO-OV127b (Phase I - II) | Randomized, open label, comparative, multi-center | Combination of durvalumab, tremelimumab with standard carboplatin-paclitaxel chemotherapy | CTLA-4 / PDL-1 Immunotherapy | Fallopian tube or primary peritoneal adenocarcinoma |
NCT02571725; INST 1419 (Phase I – II) | - | Combination of olaparib and tremelimumab | PARP-inhibition and CTLA-4 Blockade | Patients with BRCA mutation-associated OC |
NCT02785250; (Phase Ib/II) | - | DPX-Survivac and cyclophosphamide with or without epacadostat | Immunotherapeutic Vaccine (T cell activating therapy and IDO1 inhibitor) | Patients with recurrent OC |
NCT02650986 (Phase I/IIa) | Non-randomized and open label | Cyclophosphamide and TGFbdnRII | TGFβ Blockade in TCR-Engineered T-cell cancer Immunotherapy | Patients with malignancies expressing NY-ESO-1 |
NCT04034927 (Phase II) | Randomized and open label | Olaparib with or without tremelimumab | PARP-inhibition and CTLA-4 Blockade | Patients with ovarian, fallopian tube, or peritoneal cancer |
NCT05397093 (Phase Ia/Ib) | Multicenter | ITIL-306-201 | TIL cell therapy targeting folate receptor α | Epithelial ovarian cancer |
NCT03836352 (Phase II) | Open label and multicenter | Combination therapy of DPX-Survivac, cyclophosphamide, and pembrolizumab | Immunotherapeutic Vaccine | Patients with Recurrent Ovarian Cancer |
NCT03761914 (Phase I/II) | Open label, non-comparative, and multicenter | Combination of galinpepimut-S and pembrolizumab | Peptide immunotherapeutic vaccine and PD1 inhibitor | Patients with advanced ovarian cancer |
NCT00799110 (Phase II) | - | GM-CSF and Imiquimod | Dendritic Cell/Tumor Fusion Vaccine | Patients with ovarian, fallopian tube, or primary peritoneal cancer |
NCT05963100 (Phase I/II) | - | TCR-like CAR-T Cells | Modified Immune cells (chimeric antigen receptor T cells) | MSLN-positive OC patients |
NCT03907527 (Phase I/Ib) | - | PRGN-3005 UltraCAR-T cells | Autologous chimeric antigen receptor T cells | Patients with advanced-stage platinum-resistant OC |
NCT05211557 (Phase I) | Open-label, Non-randomized, and Single center | fhB7H3.CAR-T cells | Fully human scFv-armed B7H3 targeting chimeric antigen receptor T cells | Patients with recurrent advanced OC |
NCT05225363 (Phase I) | - | TAG72- CAR T cells | Modified Immune cells (chimeric antigen receptor T cells) | Platinum-resistant patients with epithelial OC |
NCT03522246 (Phase III) | Randomized, double-blind, and multicenter | Rucaparib and Nivolumab | Immune checkpoint inhibitors | Front-line treatment in newly diagnosed OC patients |
NCT05116189 (Phase III) | Randomized, and double-blind study | Pembrolizumab plus paclitaxel with or without bevacizumab and placebo plus paclitaxel with or without bevacizumab | Immune checkpoint inhibitors | Platinum-resistant recurrent OC patients |
NCT02346747 (Phase IIb) | Randomized, multicenter, double-blind, and placebo-controlled study | Vigil (Gemogenovatucel-T) | Autologous tumour cell vaccine | Maintenance in frontline stage with III/IV high-grade serous, endometrioid, or clear cell OC patients |